Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $41.20

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $41.20.

Several research firms have recently weighed in on KYMR. Oppenheimer began coverage on shares of Kymera Therapeutics in a report on Monday. They issued an “outperform” rating and a $53.00 price target for the company. Stifel Nicolaus increased their target price on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Truist Financial increased their target price on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Wolfe Research initiated coverage on shares of Kymera Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, JPMorgan Chase & Co. increased their price target on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd.

Kymera Therapeutics Price Performance

KYMR opened at $33.35 on Tuesday. The company has a market cap of $2.04 billion, a price-to-earnings ratio of -13.23 and a beta of 2.27. The firm has a 50 day simple moving average of $39.02 and a 200 day simple moving average of $28.41. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.19. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The business had revenue of $47.90 million during the quarter, compared to the consensus estimate of $41.94 million. During the same period in the previous year, the firm posted ($0.60) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 197.5% compared to the same quarter last year. As a group, analysts expect that Kymera Therapeutics will post -3.15 EPS for the current year.

Insiders Place Their Bets

In other news, Director Bruce Booth sold 71,764 shares of Kymera Therapeutics stock in a transaction on Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the sale, the director now owns 806,697 shares in the company, valued at approximately $32,638,960.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the completion of the sale, the director now owns 806,697 shares in the company, valued at approximately $32,638,960.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jared Gollob sold 46,137 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the sale, the insider now owns 74,709 shares of the company’s stock, valued at approximately $2,652,169.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 474,051 shares of company stock worth $19,624,211. 16.67% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYMR. Allspring Global Investments Holdings LLC increased its position in shares of Kymera Therapeutics by 33.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock worth $72,000 after purchasing an additional 1,310 shares during the last quarter. Quest Partners LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter worth approximately $78,000. Arizona State Retirement System bought a new position in shares of Kymera Therapeutics in the third quarter worth approximately $142,000. China Universal Asset Management Co. Ltd. increased its position in shares of Kymera Therapeutics by 352.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after purchasing an additional 5,002 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Kymera Therapeutics in the third quarter worth approximately $185,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.